首页> 外文期刊>The Journal of Urology >Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
【24h】

Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.

机译:丝裂霉素C暴露3小时和1小时后,尿路上皮癌细胞系的多药耐药性。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: The development of multidrug resistance is a problem in chemotherapy for many tumors. In vitro models of multidrug resistance require adapted cell strains that are conventionally produced from parental lines by chronic low dose drug exposure. Because adjunctive intravesical chemotherapy for superficial bladder cancer uses short courses of high dose treatment, we investigated whether such exposure of the RT112 cell line (Catalogue No. ACC 418, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) to mitomycin C, which is a common intravesical agent, would elicit multidrug resistance. MATERIALS AND METHODS: Three 1-hour exposures to graded concentrations were done at 3-week intervals. The highest mitomycin C concentrations permitting recovery in cultures and, therefore, available for examination were 3.13 and 1.06 microg/ml. Cross-resistance to epirubicin in surviving cultures was visualized by confocal microscopy and quantified by MTT residual viable biomass assay. Spheroids were made by the agarose technique and exposed to high dose mitomycin C to assess the probability that the relevant concentrations might be found clinically in some cell layers of a superficial lesion. RESULTS: Resistance was induced by 3 short drug exposures. The evidence for this was functional (MTT assay) and by intracellular localization. Toxicity to an alternative multidrug resistance class drug was lowered in surviving clones and nuclear exclusion of the drug was noted. Spheroid experiments showed sharp gradients of incorporated drug across the outermost layers of cells, suggesting that a proportion of cells in clinical superficial bladder cancer would be exposed to drug at concentrations that generated the resistant clones in these experiments. CONCLUSIONS: We report multidrug resistance induction using 2 independent methodologies. The results have implications for the development of experimental models and the likelihood of resistance resulting from clinical regimens. Brief exposure can elicit detectable resistance. It is arguable that selective rather than instructive mechanisms are involved, and the levels of drug required are likely to exist in a superficial transitional cell carcinoma frond exposed at its surface to high drug concentrations.
机译:目的:多药耐药性的发展是许多肿瘤化疗中的一个问题。多重耐药性的体外模型需要适应的细胞株,这些细胞株通常是通过长期低剂量药物暴露从亲本系产生的。由于用于浅表性膀胱癌的辅助膀胱内化疗使用的是短期的高剂量治疗方案,因此我们调查了RT112细胞系(目录号ACC 418,德国不伦瑞克的德国森姆龙·冯·米克罗有机主义和Zellkulturen公司)对丝裂霉素C的这种暴露情况。普通的膀胱内药物会引起多药耐药性。材料与方法:每隔3周间隔进行3次1小时的分级浓度暴露。丝裂霉素C的最高浓度允许在培养物中恢复,因此可用于检查的浓度为3.13和1.06 microg / ml。通过共聚焦显微镜观察存活的培养物中对表柔比星的交叉抗性,并通过MTT残留的可行生物量测定法定量。通过琼脂糖技术制备球体,并将其暴露于高剂量丝裂霉素C中,以评估在临床上浅表病变的某些细胞层中可能发现相关浓度的可能性。结果:3次短暂的药物接触引起耐药性。证据是功能性的(MTT分析)和细胞内定位。在幸存的克隆中降低了对另一种多药耐药类药物的毒性,并注意到该药物的核排斥。球状实验表明,掺入的药物在细胞最外层之间呈陡峭的梯度,这表明临床浅表性膀胱癌中的一部分细胞会以这些实验中产生抗性克隆的浓度暴露于药物。结论:我们报告了使用两种独立的方法诱导多药耐药性。这些结果对实验模型的开发以及临床方案产生耐药性的可能性具有影响。短暂暴露可以引起可检测的抗性。可能涉及选择性机制而不是指导性机制,在表面暴露于高浓度药物的浅表移行细胞癌中可能存在所需的药物水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号